# Monitoring the Efficacy of Duvalizumab Combined With Neoadjuvant Chemotherapy for Ib-IIIb NSCLC by Sequencing of Immune Receptor Repertoire: a Prospective, One Arm Clinical Study

> **NCT04897386** · PHASE2 · UNKNOWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 30 (estimated)

## Conditions studied

- Ib-IIIb NSCLC

## Interventions

- **DRUG:** Duvalizumab

## Key facts

- **NCT ID:** NCT04897386
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04897386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04897386, "Monitoring the Efficacy of Duvalizumab Combined With Neoadjuvant Chemotherapy for Ib-IIIb NSCLC by Sequencing of Immune Receptor Repertoire: a Prospective, One Arm Clinical Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04897386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*